ClinicalTrials.gg
CompletedNCT04877990Updated Sep 24, 2024Results posted

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

A Phase 2 interventional study of Deucravacitinib in Crohn Disease and Ulcerative Colitis, sponsored by Bristol-Myers Squibb. Completed at 43 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Crohn Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Crohn Disease · Bristol-Myers Squibb.

Enrollment
12th of 16
67 · median 180
Started
2021
the only one that year
Phase 2
6 of 16
none open now
Registered
15th of 16
by date

Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, this one is the 12th largest by enrollment, is the only one that started in 2021, is one of 6 in phase 2, and was the 15th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 16 studies in Crohn Disease by Bristol-Myers Squibb is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Crohn Disease by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and efficacy of Deucravacitinib in participants who have previously been enrolled in a Deucravacitinib Phase 2 study for moderate to severe Crohn's disease or moderate to severe Ulcerative Colitis.

03

Conditions studied

  • Crohn Disease
  • Ulcerative Colitis

Keywords

  • BMS-986165
  • Crohn Colitis
  • Crohn Disease
  • Crohn Iliocolitis
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Deucravacitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously completed open-label extension treatment in one of the parent Crohn's disease or ulcerative colitis studies

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Current colonic adenomas or dysplasia diagnosed at the endoscopy performed at the end of treatment visit of the parent study or past confirmed colonic dysplasia in the parent study that has not been eradicated

Other protocol-defined inclusion/exclusion criteria apply

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Long-Term Extension Rollover Study: Deucravacitinib

    Drug: Deucravacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment

    Time frame: From first dose to 30 days post last dose (Up to 110 weeks)

  2. Number of Participants With Laboratory Abnormalities

    Number of participants experiencing abnormalities in laboratory testing including chemistry, hematology, and renal.

    Time frame: From first dose to 30 days post last dose (Up to 110 weeks)

  3. Number of Participants With Electrocardiogram (ECG) Abnormalities

    Time frame: From first dose to 30 days post last dose (Up to 110 weeks)

  4. Number of Participants With Vital Signs Abnormalities

    Time frame: From first dose to 30 days post last dose (Up to 110 weeks)

  5. Change From Baseline in Laboratory Parameters

    Change from baseline in laboratory parameters including lipid profile, chemistry liver function, chemistry (other), and chemistry renal function

    Time frame: Baseline, Week 12, Week 108

  6. Change From Baseline in Electrocardiogram (ECG) Parameters - ECG Mean Heart Rate

    Changes from IM011077 study baseline in electrocardiogram (ECG) parameters - ECG mean heart rate

    Time frame: Baseline, Week 48, Week 96

  7. Change From Baseline in Electrocardiogram (ECG) Parameters

    Changes from IM011077 study baseline in electrocardiogram (ECG) parameters

    Time frame: Baseline, Week 48, Week 96

  8. Change From Baseline in Vital Signs Parameters - Heart Rate

    Changes from IM011077 study baseline in vital signs parameters - heart rate

    Time frame: Baseline, Week 12, Week 108

  9. Change From Baseline in Vital Signs Parameters

    Changes from IM011077 study baseline in vital signs parameters

    Time frame: Baseline, Week 12, Week 108

07

Results

Posted Sep 24, 2024

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneCrohn's DiseaseUlcerative Colitis
Started2641
Completed2441
Not completed20
Treatment
Participant flow — Treatment
MilestoneCrohn's DiseaseUlcerative Colitis
Started2441
Completed00
Not completed2441
Withdrew: Other reasons31
Withdrew: Administrative reasons by sponsor1733
Withdrew: Withdrawal by subject26
Withdrew: Adverse event21

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment

Time frame:
From first dose to 30 days post last dose (Up to 110 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsCrohn's DiseaseUlcerative Colitis
TEAEs1819
TESAEs22
TEAEs leading to study discontinuation11
AEs of Interest - Skin-related events02
AEs of Interest - Creatine Kinase events23
PrimaryNumber of Participants With Laboratory Abnormalities

Number of participants experiencing abnormalities in laboratory testing including chemistry, hematology, and renal.

Time frame:
From first dose to 30 days post last dose (Up to 110 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsCrohn's DiseaseUlcerative Colitis
Sodium < 130 or > 150 MEQ/L (MMOL/L)00
Potassium < 3 or > 5.5 MEQ/L (MMOL/L)01
Calcium > 12.5 MG/DL00
Fasting Serum Glucose < 50 MG/DL or > 250 MG/DL00
Albumin < 2.0 G/DL00
Creatine Kinase > 10xupper limit of normal00
Hemoglobin < 7.0 G/DL or > 30% reduction from baseline00
Hematocrit < 20% or 30% reduction from baseline00
White Blood Cell Count < 1.5 x 10^9/L or > 35 x 10^9/L00
Lymphocyte Count < 0.5 x 10^9/L00
Neutrophil Count < 0.75 x 10^9/L00
Platelet Count < 75 x 10^9/L or > 999 x 10^9/L00
Serum Creatinine Increase > 50% and > 44.2 UMOL/L00
PrimaryNumber of Participants With Electrocardiogram (ECG) Abnormalities
Time frame:
From first dose to 30 days post last dose (Up to 110 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsCrohn's DiseaseUlcerative Colitis
QTCF (MSEC) 450 - < 48010
QTCF (MSEC) 480 - < 50001
QTCF (MSEC) >= 50000
30 < CHANGE FROM IM011077 STUDY BASELINE <= 60 MSEC30
CHANGE FROM IM011077 STUDY BASELINE > 60 MSEC35
PRAG (MSEC) P WAVE AND R WAVE (PR) INTERVAL >= 240 MSEC00
QRSAG(MSEC) QRS INTERVAL >= 200 MSEC00
PrimaryNumber of Participants With Vital Signs Abnormalities
Time frame:
From first dose to 30 days post last dose (Up to 110 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Abnormalities
ParticipantsCrohn's DiseaseUlcerative Colitis
HEART RATE (BEATS/MIN): VALUE > 100 AND CHANGE FROM IM011077 STUDY BASELINE > 3011
HEART RATE (BEATS/MIN): VALUE < 55 AND CHANGE FROM IM011077 STUDY BASELINE < -1510
SYSTOLIC BLOOD PRESSURE (MMHG): VALUE > 140 AND CHANGE FROM IM011077 STUDY BASELINE > 2035
SYSTOLIC BLOOD PRESSURE (MMHG): VALUE < 90 AND CHANGE FROM IM011077 STUDY BASELINE < -2000
DIASTOLIC BLOOD PRESSURE (MMHG): VALUE > 90 AND CHANGE FROM IM011077 STUDY BASELINE > 1035
DIASTOLIC BLOOD PRESSURE (MMHG): VALUE < 55 AND CHANGE FROM IM011077 STUDY BASELINE < -1000
PrimaryChange From Baseline in Laboratory Parameters

Change from baseline in laboratory parameters including lipid profile, chemistry liver function, chemistry (other), and chemistry renal function

Time frame:
Baseline, Week 12, Week 108
Reported as:
Mean · mg/dL
Change From Baseline in Laboratory Parameters
mg/dLCrohn's DiseaseUlcerative Colitis
Cholesterol, Fasting Week 1210.20 ± 7.207-9.17 ± 4.629
Cholesterol, Fasting Week 108-12.00 ± NA—
HDL Cholesterol, Fasting Week 12-0.75 ± 3.400-0.83 ± 2.626
HDL Cholesterol, Fasting Week 1080.00 ± NA—
LDL Cholesterol, Fasting Week 124.75 ± 4.270-6.50 ± 4.689
LDL Cholesterol, Fasting Week 1081.00 ± NA—
Triglycerides, Fasting Week 122.3 ± 11.313.2 ± 4.78
Triglycerides, Fasting Week 108-62.0 ± NA—
Bilirubin, Week 120.0650 ± 0.050280.0043 ± 0.03566
Bilirubin, Week 108-0.1000 ± 0.00000—
Glucose, Fasting Serum Week 121.75 ± 0.9460.80 ± 1.114
Glucose, Fasting Serum Week 10829.00 ± NA—
Calcium, Week 120.152 ± 0.09150.041 ± 0.0612
Calcium, Week 1080.350 ± 0.1500—
Creatinine, Week 12-0.008 ± 0.01820.004 ± 0.0153
Creatinine, Week 1080.080 ± 0.0100—
Phosphate, Week 120.153 ± 0.08930.019 ± 0.1198
Phosphate, Week 108-0.150 ± 0.1500—
Urea Nitrogen, Week 12-0.269 ± 1.06310.511 ± 0.5902
Urea Nitrogen, Week 1085.500 ± 0.5000—
PrimaryChange From Baseline in Electrocardiogram (ECG) Parameters - ECG Mean Heart Rate

Changes from IM011077 study baseline in electrocardiogram (ECG) parameters - ECG mean heart rate

Time frame:
Baseline, Week 48, Week 96
Reported as:
Mean · beats/min
Change From Baseline in Electrocardiogram (ECG) Parameters - ECG Mean Heart Rate
beats/minCrohn's DiseaseUlcerative Colitis
ECG Mean Heart Rate, Week 48-1.4 ± 9.212.6 ± 12.76
ECG Mean Heart Rate, Week 96-1.0 ± 11.27-1.0 ± NA
PrimaryChange From Baseline in Electrocardiogram (ECG) Parameters

Changes from IM011077 study baseline in electrocardiogram (ECG) parameters

Time frame:
Baseline, Week 48, Week 96
Reported as:
Mean · msec
Change From Baseline in Electrocardiogram (ECG) Parameters
msecCrohn's DiseaseUlcerative Colitis
PR Interval, Aggregate, Week 489.1 ± 20.62-2.4 ± 22.65
PR Interval, Aggregate, Week 9614.7 ± 16.56-22.0 ± NA
QRS Duration, Aggregate, Week 48-1.2 ± 8.47-0.9 ± 8.53
QRS Duration, Aggregate, Week 96-9.3 ± 2.890.0 ± NA
QT Interval, Aggregate, Week 4818.6 ± 30.337.6 ± 40.35
QT Interval, Aggregate, Week 9627.0 ± 62.5596.0 ± NA
QTcB Interval, Aggregate, Week 48-2.3 ± 21.787.7 ± 19.41
QTcF Interval, Aggregate, Week 48-20.6388 ± 197.4947231.1621 ± 141.14597
QTcF Interval, Aggregate, Week 96-86.9797 ± 198.61888101.0000 ± NA
PrimaryChange From Baseline in Vital Signs Parameters - Heart Rate

Changes from IM011077 study baseline in vital signs parameters - heart rate

Time frame:
Baseline, Week 12, Week 108
Reported as:
Mean · beats/min
Change From Baseline in Vital Signs Parameters - Heart Rate
beats/minCrohn's DiseaseUlcerative Colitis
Heart Rate Week 123.6 ± 11.890.9 ± 10.71
Heart Rate Week 1081.0 ± NA—
PrimaryChange From Baseline in Vital Signs Parameters

Changes from IM011077 study baseline in vital signs parameters

Time frame:
Baseline, Week 12, Week 108
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs Parameters
mmHgCrohn's DiseaseUlcerative Colitis
Systolic Blood Pressure Week 123.8 ± 11.563.8 ± 13.62
Systolic Blood Pressure Week 1084.0 ± NA—
Diastolic Blood Pressure Week 120.3 ± 7.82-1.3 ± 7.38
Diastolic Blood Pressure Week 1089.0 ± NA—

Adverse events

Collected over SAEs and AEs are assessed from first dose to 30 days post last dose (Up to 110 weeks). Participants were assessed for all-cause mortality from their first dose to study completion (Up to 120 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CROHN'S DISEASE0/26 (0%)2/24 (8.3%)12/24 (50%)
ULCERATIVE COLITIS0/41 (0%)2/41 (4.9%)13/41 (31.7%)
Most frequent serious events
Most frequent serious events
EventCROHN'S DISEASEULCERATIVE COLITIS
Small intestinal obstructionGastrointestinal disorders1/240/41
PneumoniaInfections and infestations1/240/41
SepsisInfections and infestations1/240/41
Urinary tract infectionInfections and infestations1/240/41
Cardiac failure chronicCardiac disorders0/241/41
Colitis ulcerativeGastrointestinal disorders0/241/41
General physical health deteriorationGeneral disorders0/241/41
Procedural pneumothoraxInjury, poisoning and procedural complications0/241/41
Most frequent other events
Most frequent other events
EventCROHN'S DISEASEULCERATIVE COLITIS
COVID-19Infections and infestations6/243/41
NasopharyngitisInfections and infestations3/240/41
PneumoniaInfections and infestations3/240/41
Upper respiratory tract infectionInfections and infestations2/245/41
Mouth ulcerationGastrointestinal disorders2/241/41
PyrexiaGeneral disorders2/241/41
CoughRespiratory, thoracic and mediastinal disorders2/241/41
Colitis ulcerativeGastrointestinal disorders0/243/41
TonsillitisInfections and infestations0/243/41
DepressionPsychiatric disorders0/243/41

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Crohn's DiseaseUlcerative ColitisTotal
Mean38.7 ± 14.0844.3 ± 15.7042.2 ± 15.24
Sex: Female, Male
Sex: Female, Male(Participants)Crohn's DiseaseUlcerative ColitisTotal
Female101929
Male162238
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Crohn's DiseaseUlcerative ColitisTotal
Hispanic or Latino011
Not Hispanic or Latino213556
Unknown or Not Reported5510
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Crohn's DiseaseUlcerative ColitisTotal
White213859
Black or African American101
Asian202
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Other000
Asian Indian000
Chinese202
Japanese033
Asian Other000
08

Study locations

43 sites
  • Local Institution - 0036
    Shreveport, Louisiana 71105, United States
  • Local Institution - 0002
    Wyoming, Michigan 49519, United States
  • Local Institution - 0037
    Jackson, Mississippi 39216, United States
  • Local Institution - 0041
    Cleveland, Ohio 44195, United States
  • Local Institution - 0038
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0066
    Charleston, South Carolina 29425, United States
  • Local Institution - 0053
    Garland, Texas 75044, United States
  • Local Institution - 0056
    San Antonio, Texas 78229, United States
  • Local Institution - 0049
    Tyler, Texas 75701, United States
  • Local Institution - 0055
    Richmond, Virginia 23249, United States
  • Local Institution - 0013
    Ballarat, Victoria 3350, Australia
  • Local Institution - 0050
    Vaughan, Ontario L4L 4Y7, Canada
  • Local Institution - 0030
    Guangzhou, Guangdong 510080, China
  • Local Institution - 0029
    Guangzhou, Guangdong 510655, China
  • Local Institution - 0012
    Kiel, 24105, Germany
  • Local Institution - 0062
    Budapest, 1083, Hungary
  • Local Institution - 0023
    Budapest, 1088, Hungary
  • Humanitas
    Rozzano, Lombardia 20089, Italy
  • Fondazione Irccs - Policlinico San Matteo
    Pavia, 27100, Italy
  • Local Institution - 0063
    Hirosaki, Aomori 036-8545, Japan
  • Local Institution - 0047
    Sagamihara, Kanagawa 252-0375, Japan
  • Local Institution - 0027
    Saga-shi, Saga 8498501, Japan
  • Local Institution - 0026
    Bunkyo-ku, Tokyo 1138519, Japan
  • Local Institution - 0044
    Minato-ku, Tokyo 105-8471, Japan
  • Local Institution - 0060
    Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • Local Institution - 0046
    Nowy Targ, Małopolskie 34-400, Poland
  • Local Institution - 0022
    Bydgoszcz, 85-231, Poland
  • Local Institution - 0003
    Bydgoszcz, 85-794, Poland
  • Local Institution - 0001
    Krakow, 31-501, Poland
  • Local Institution - 0028
    Sopot, 81-756, Poland
  • Local Institution - 0025
    Szczecin, 71-434, Poland
  • Local Institution - 0035
    Warsaw, 00-728, Poland
  • Local Institution - 0048
    Warsaw, 02-798, Poland
  • Local Institution - 0004
    Warszawa, 03-712, Poland
  • Local Institution - 0018
    Wroclaw, 53-114, Poland
  • Local Institution - 0061
    Tychy, Śląskie 43-100, Poland
  • Local Institution - 0054
    Santa Maria da Feira, 4520-211, Portugal
  • Local Institution
    Bucharest, 020125, Romania
  • Local Institution
    Irkutsk, 664033, Russian Federation
  • Local Institution
    Saint-Petersburg, 195257, Russian Federation
  • Local Institution - 0045
    Fuenlabrada, Madrid 28942, Spain
  • Local Institution - 0064
    Taipei, 10002, Taiwan
  • Local Institution - 0034
    Morriston, SA6 6NL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Aug 2023, 27 months.

Results were first posted in Sep 2024, 1 year after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 27 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
May 7, 2021
StartActual
May 7, 2021
Primary completionActual
Aug 29, 2023
CompletionActual
Aug 29, 2023
Results first posted
Sep 24, 2024
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04877990
Responsible party
Sponsor
First posted
May 7, 2021
Start date
May 7, 2021
Primary completion
Aug 29, 2023
Completion
Aug 29, 2023
Results posted
Sep 24, 2024
Last update
Sep 24, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion